Compare Stocks → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:APRETSE:PLINASDAQ:TH Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$5.35+3.5%$6.40$2.78▼$8.85$28.07M1.038,045 shs9,079 shsPLIProMetic Life SciencesC$13.60C$7.13▼C$590.00C$317.06MN/A8,002 shs921 shsTHTarget Hospitality$11.08+0.6%$9.94$8.49▼$16.80$1.11B2.09447,174 shs408,308 shs7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics+5.52%-8.39%-9.63%+2.88%+40.05%PLIProMetic Life Sciences0.00%0.00%0.00%0.00%0.00%THTarget Hospitality+0.64%+1.84%+1.56%+16.26%-10.28%World’s biggest multibillionaire investor is buying THIS by the ton [picture] (Ad)Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPREAprea Therapeutics2.834 of 5 stars3.55.00.00.00.03.30.6PLIProMetic Life SciencesN/AN/AN/AN/AN/AN/AN/AN/ATHTarget Hospitality1.6429 of 5 stars1.35.00.00.01.31.72.5Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPREAprea Therapeutics3.00Buy$15.50189.72% UpsidePLIProMetic Life SciencesN/AN/AN/AN/ATHTarget Hospitality2.50Moderate Buy$11.00-0.72% DownsideCurrent Analyst RatingsLatest TH, APRE, PLI, and TLX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/12/2024THTarget HospitalityStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$13.00 ➝ $12.003/27/2024APREAprea TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$9.00 ➝ $11.003/26/2024APREAprea TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.003/26/2024THTarget HospitalityStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.003/25/2024THTarget HospitalityOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$12.00 ➝ $10.003/14/2024THTarget HospitalityStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $13.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPREAprea Therapeutics$580K50.09N/AN/A$4.54 per share1.18PLIProMetic Life SciencesC$39.91M0.00N/A3.94C$6.07 per share0.00THTarget Hospitality$563.61M1.98$2.51 per share4.41$3.71 per share2.99Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPREAprea Therapeutics-$14.29M-$3.99N/AN/AN/AN/A-65.58%-52.37%5/20/2024 (Estimated)PLIProMetic Life SciencesN/A-C$63.06N/AN/AN/AN/AN/AN/AN/ATHTarget Hospitality$173.70M$1.547.1916.061.1529.53%53.91%24.85%5/14/2024 (Estimated)Latest TH, APRE, PLI, and TLX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/26/2024Q4 2023APREAprea Therapeutics-$0.56-$0.92-$0.36-$0.92$0.33 million$0.01 million3/13/2024Q4 2023THTarget Hospitality$0.24$0.29+$0.05$0.29$118.00 million$126.20 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPREAprea TherapeuticsN/AN/AN/AN/AN/APLIProMetic Life SciencesN/AN/AN/AN/AN/ATHTarget HospitalityN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPREAprea TherapeuticsN/A5.135.13PLIProMetic Life Sciences37.474.063.66THTarget Hospitality0.472.572.57OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPREAprea Therapeutics34.19%PLIProMetic Life SciencesN/ATHTarget Hospitality32.40%Insider OwnershipCompanyInsider OwnershipAPREAprea Therapeutics20.90%PLIProMetic Life SciencesN/ATHTarget Hospitality68.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAPREAprea Therapeutics75.43 million4.30 millionNo DataPLIProMetic Life Sciences48723.31 millionN/ANot OptionableTHTarget Hospitality984100.52 million31.97 millionNot OptionableTH, APRE, PLI, and TLX HeadlinesSourceHeadlineKSA unleashes massive hospitality expansion – and a wealth of investment opportunitiesbreakingtravelnews.com - April 26 at 4:30 AMChatrium Grand Bangkok Wins Coveted LIV Hospitality Design Award for Stunning Designnewswit.com - April 25 at 11:30 PMBCCP highlights opportunities in travel industry in '4th Travel Talks'msn.com - April 23 at 9:25 PMAston Villa 3-1 AFC Bournemouthavfc.co.uk - April 23 at 9:25 PMJason P. Vlacich Implements A Sell Strategy: Offloads $582K In Target Hospitality Stockbenzinga.com - April 16 at 12:41 PM1,349,167 Shares in Target Hospitality Corp. (NASDAQ:TH) Bought by Voss Capital LLCmarketbeat.com - April 15 at 7:42 PMBournemouth vs Man Utd live: Score and latest updates from Vitality Stadiummsn.com - April 13 at 11:02 PMVanguard Group Inc. Acquires 523,398 Shares of Target Hospitality Corp. (NASDAQ:TH)marketbeat.com - April 13 at 4:31 AMTarget Hospitality Corp. (NASDAQ:TH) Short Interest Down 37.7% in Marchmarketbeat.com - April 12 at 3:16 PMHold Rating Maintained Amidst Acquisition Bid and Growth Prospects for Target Hospitalitymarkets.businessinsider.com - April 12 at 11:57 AMThe Analyst Landscape: 4 Takes On Target Hospitalitymarkets.businessinsider.com - April 12 at 11:57 AMDocuSign upgraded, Arista downgraded: Wall Street's top analyst callsfinance.yahoo.com - April 12 at 11:57 AMTarget Hospitality's (TH) "Hold" Rating Reiterated at Stifel Nicolausmarketbeat.com - April 12 at 8:23 AMTarget Hospitality Announces Partnership with Chard Métis Dene Groupfinance.yahoo.com - April 12 at 6:57 AMTarget Hospitality Announces Partnership with Chard Métis Dene Groupprnewswire.com - April 12 at 6:45 AMRosie Holidays opens new gallery to mark its 50th anniversaryfbcnews.com.fj - April 11 at 10:48 PMWall Street Favorites: 3 Under-$20 Stocks With Strong Buy Ratings for April 2024investorplace.com - April 11 at 1:46 PMTarget Hospitality Corp (TH)investing.com - April 11 at 12:47 PMKent Lake Capital LLC Lowers Position in Target Hospitality Corp. (NASDAQ:TH)marketbeat.com - April 6 at 7:36 PMWhy Target Hospitality Stock Surged Higher This Weekfool.com - March 28 at 1:31 PMTarget Hospitality Corp.cnn.com - March 27 at 10:24 AMTarget Hospitality's (TH) "Buy" Rating Reaffirmed at Stifel Nicolausmarketbeat.com - March 26 at 10:46 AMArrow offers to buy remaining stake Target Hospitalitymsn.com - March 25 at 7:51 PMTarget Hospitality jumps after $10.80 a share takeover offermsn.com - March 25 at 7:51 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains ImminentCaterpillar’s Market Reset Isn’t Over: Get Ready for Lower PricesApril 25, 2024 10:36 AMView Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to ComeCharles Schwab Fortifies its Uptrend on EPS Beat April 23, 2024 10:15 AMView Charles Schwab Fortifies its Uptrend on EPS Beat All Headlines Company DescriptionsAprea TherapeuticsNASDAQ:APREAprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.ProMetic Life SciencesTSE:PLIPrometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.Target HospitalityNASDAQ:THTarget Hospitality Corp. operates as a specialty rental and hospitality services company in North America. The company operates through two segments, Hospitality & Facilities Services - South and Government. It owns a network of specialty rental accommodation units. In addition, the company provides catering and food, maintenance, housekeeping, grounds-keeping, security, health and recreation facilities, workforce community management, concierge, and laundry services. It serves the U.S. government contractors and investment grade natural resource development companies. Target Hospitality Corp. was founded in 1978 and is headquartered in The Woodlands, Texas. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.